Using superparamagnetic iron oxide-enhanced MRI to differentiate metastatic hepatic tumors and nonsolid benign lesions.

OBJECTIVE We evaluated the ability of superparamagnetic iron oxide (SPIO)-enhanced MRI to differentiate solid metastatic tumors and nonsolid benign lesions by clarifying the characteristic signal-intensity pattern of each lesion on SPIO-enhanced T2-weighted and heavily T1-weighted gradient-echo images. MATERIALS AND METHODS SPIO-enhanced MRI was performed using a 1.5-T system in 33 consecutive patients without cirrhosis who had 81 focal hepatic lesions (42 cysts, 13 hemangiomas, 26 metastatic tumors). The relative signal intensity of lesions on SPIO-enhanced heavily T1- and T2-weighted gradient-echo images was classified into one of the following three categories: high intensity, isointensity, or low intensity relative to the surrounding liver parenchyma. The diagnostic accuracy for differentiating solid metastatic tumors from nonsolid benign lesions (cysts or hemangiomas) was determined. RESULTS A combination of the relative signal intensity of the lesion on T2- and heavily T1-weighted gradient-echo images could be classified into the following five categories: high intensity and high intensity (category 1), high intensity and isointensity (category 2), high intensity and low intensity (category 3), isointensity and isointensity (category 4), and isointensity and low intensity (category 5). According to these categories, category 1 contained two hemangiomas, category 2 had 11 hemangiomas, category 3 had 25 metastatic tumors and two cysts, category 4 had three cysts, and category 5 had 37 cysts and one metastatic tumor. When a tumor with a relative signal intensity of categories 1 or 2 was considered to be a hemangioma (category 3 metastatic tumors and categories 4 and 5 cysts), diagnostic accuracy for characterizing such hepatic lesions was 96% (78/81). CONCLUSION When evaluating metastatic liver tumors on SPIO-enhanced MRI, we recommend that heavily T1- and T2-weighted gradient-echo images be obtained with our parameters to exclude hemangiomas or cysts.

[1]  S DeSena,et al.  Detection of hepatic lesions in candidates for surgery: comparison of ferumoxides-enhanced MR imaging and dual-phase helical CT. , 2000, AJR. American journal of roentgenology.

[2]  S E Seltzer,et al.  Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. , 1995, Radiology.

[3]  V. Servois,et al.  Hepatic tumors: detection and characterization at 1-T MR imaging enhanced with AMI-25. , 1994, Radiology.

[4]  D. Choi,et al.  Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced mr imaging versus combined helical CT during arterial portography and CT hepatic arteriography. , 2001, AJR. American journal of roentgenology.

[5]  Myeong-Jin Kim,et al.  Characterization of focal hepatic lesions with ferumoxides‐enhanced MR imaging: Utility of T1‐weighted spoiled gradient recalled echo images using different echo times , 2002, Journal of magnetic resonance imaging : JMRI.

[6]  P. Robinson,et al.  Hepatic lesion detection after superparamagnetic iron oxide enhancement: comparison of five T2-weighted sequences at 1.0 T by using alternative-free response receiver operating characteristic analysis. , 2000, Radiology.

[7]  D. Lu,et al.  Comparison of dynamic gadolinium‐enhanced and ferumoxides‐enhanced MRI of the liver on high‐ and low‐field scanners , 2004, Journal of magnetic resonance imaging : JMRI.

[8]  C. Marx,et al.  Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis. , 2000, Radiology.

[9]  B. V. Van Beers,et al.  Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. , 1996, Radiology.

[10]  Takashi Kobayashi.  Re: Cancer cells in mesenteric vein and peripheral vessels by measuring telomerase activity in patients with colorectal cancer. , 2004, Surgery.

[11]  P. Robinson,et al.  Hepatic lesion detection: comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis. , 1999, Radiology.

[12]  D. Khayat,et al.  Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. , 1994, Radiology.

[13]  B. Marincek,et al.  Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. , 1995, Radiology.

[14]  R Weissleder,et al.  Superparamagnetic iron oxide: pharmacokinetics and toxicity. , 1989, AJR. American journal of roentgenology.

[15]  M Georgi,et al.  MRI with superparamagnetic iron oxide: efficacy in the detection and characterization of focal hepatic lesions. , 1999, Magnetic resonance imaging.

[16]  P. Robinson,et al.  Hepatic lesion detection at MR imaging: a comparative study with four sequences. , 1997, Radiology.

[17]  W. Pegios,et al.  Superparamagnetic iron oxide--enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions. , 1996, Radiology.

[18]  P. Mergo,et al.  Characterization of focal hepatic lesions with ferumoxides-enhanced T2-weighted MR imaging. , 2000, AJR. American journal of roentgenology.

[19]  T. Murakami,et al.  Superparamagnetic iron oxide–enhanced magnetic resonance images of hepatocellular carcinoma: Correlation with histological grading , 2000, Hepatology.

[20]  M Oudkerk,et al.  Hepatic lesions: detection with ferumoxide-enhanced T1-weighted MR imaging. , 1997, Radiology.